

## ANDREW B. WOLF, MD

### CONTACT INFORMATION

---

12631 E. 17th Avenue  
Mail Stop B185  
Aurora, CO 80045

Phone: (303) 724-4328  
Fax: (303) 724-0985  
[andrew.wolf@cuanschutz.edu](mailto:andrew.wolf@cuanschutz.edu)

### ACADEMIC APPOINTMENTS

---

Assistant Professor, Neuroimmunology Section	7/2023-Present
Associate Program Director, Neuroimmunology Fellowship	7/2023-Present
Faculty, Rocky Mountain MS Center	7/2023-Present
Faculty, Neuroinfectious Diseases Group	7/2023-Present
Department of Neurology, University of Colorado School of Medicine, Aurora, CO	

### EDUCATION

---

Bachelor of Science (Physiology & Behavior)	5/2010
Arizona State University, Tempe, AZ	
Master of Science (Neuroscience)	4/2016
Doctor of Medicine (Clinical Medicine)	5/2018
University of Colorado School of Medicine, Aurora, CO	

### CLINICAL TRAINING

---

Internal Medicine Internship	6/2018-6/2019
Department of Medicine, University of Colorado School of Medicine, Aurora, CO	
Neurology Residency	7/2019-6/2022
Chief Residency	7/2021-6/2022
Neuroimmunology Fellowship	7/2022-6/2023
Department of Neurology, University of Colorado School of Medicine, Aurora, CO	

### MEDICAL LICENSURE

---

Colorado Medical Board, Physician Training License, #0007057	4/2018-2/2022
Colorado Medical Board, Physician License, #0068220	2/2022-Present

### BOARD CERTIFICATION

---

Neurology, American Board of Psychiatry and Neurology, Certificate 64702	9/2022-Present
--	----------------

### CLINICAL PRIVILEGES

---

Denver Health Medical Center, Denver, CO	7/2022-Present
University of Colorado Hospital, Aurora, CO	7/2022-Present
DAWN Clinic, Aurora, CO	7/2023-Present

## PEER-REVIEWED PUBLICATIONS

---

- 1.) Valla J\*, Yaari R\*, **Wolf AB**, Kusne Y, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM (2010). Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the *APOE*  $\epsilon$ 4 allele, the major late-onset Alzheimer's susceptibility gene. *J Alzheimers Dis*, 22: 307-313. DOI 10.3233/JAD-2010-100129. \*Contributed equally
- 2.) **Wolf AB**, Braden BB, Bimonte-Nelson H, Kusne Y, Young N, Engler-Chiurazzi E, Garcia AN, Walker DG, Moses GSD, Tran H, LaFerla FM, Lue L, Emerson Lombardo N, Valla J (2012). Broad-based nutritional supplementation in 3xTG mice corrects mitochondrial function and indicates sex-specificity in response to Alzheimer's intervention. *J Alzheimers Dis*, 24: 445-460. DOI 10.3233/JAD-2012-120478.
- 3.) **Wolf AB**, Caselli RJ, Reiman EM, Valla J (2013). *APOE* & neuroenergetics: an emerging paradigm in Alzheimer's disease. *Neurobiol Aging*, 34: 1007-1017. DOI 10.1016/j.neurobiolaging.2012.10.011.
- 4.) Hardesty DA, **Wolf AB**, Brachman DG, McBride HL, Youssef EF, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2013). The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. *J Neurosurg*, 119: 475-481. DOI 10.3171/2012.12.JNS12414.
- 5.) **Wolf AB**, Valla J, Bu G, Kim J, LaDu MJ, Reiman EM, Caselli RJ (2013). Apolipoprotein E as a  $\beta$ -amyloid independent factor in Alzheimer's disease. *Alzheimers Res Ther*, 5: 38. DOI 10.1186/alzrt204.
- 6.) Snyder LA, **Wolf AB**, Oppenlander ME, Bina R, Wilson JR, Ashby L, Brachman DG, Coons SW, Spetzler RF, Sanai N (2014). The impact of extent of resection on malignant transformation of pure oligodendrogliomas. *J Neurosurg*, 120: 309-314. DOI 10.3171/2013.10.JNS13368.
- 7.) Oppenlander ME, **Wolf AB**, Snyder LA, Bina R, Wilson JR, Coons SW, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N (2014). An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *J Neurosurg*, 120: 846-853. DOI 10.3171/2013.12.JNS13184.
- 8.) **Wolf AB**, Lintz MJ, Costabile JD, Thompson JA, Stubblefield EA, Felsen G (2015). An integrative role for the superior colliculus in selecting targets for movements. *J Neurophysiol*, 114: 2118-2131. DOI 10.1152/jn.00262.2015.
- 9.) Perkins M, **Wolf AB**, Chavira B, Shonebarger D, Meckel JP, Leung L, Ballina L, Ly S, Jones TB, Vallejo J, Jentarra G, Valla J (2016). Altered energy metabolism pathways in the posterior cingulate in young adult apolipoprotein E  $\epsilon$ 4 Carriers. *J Alzheimers Dis*, 53: 95-106. DOI 10.3233/JAD-151205.
- 10.) Kusne Y\*, **Wolf AB\***, Townley K, Conway M, Peyman GA (2017). Visual system manifestations of Alzheimer's disease. *Acta Ophthalmol*, 95: 668-676. DOI 10.1111/aos.13319. \*Contributed equally
- 11.) **Wolf AB** & Felsen G (2019). How public health policy can be informed by neuroscience. *Behav Public Policy*, 3: 37-46. DOI 10.1017/bpp.2017.9.

- 12.) **Wolf AB**, Zhovtis Ryerson L, Pandey K, Vollmer T, Corboy JR, Alvarez E (2019). Rituximab-induced serum sickness in multiple sclerosis patients. *Mult Scler Relat Disord*, 36: 101402. DOI 10.1016/j.msard.2019.101402.
- 13.) **Wolf AB** & Alvarez E (2021). COVID-19 vaccination in patients with multiple sclerosis on disease-modifying therapy. *Neurol Clin Pract*, 11: 358-361. DOI 10.1212/CPJ.0000000000001088.
- 14.) Shiao JC\*, **Wolf AB**\*, Rabinovitch RA, Smith C, Kleinschmidt-Demasters BK, Ney DE (2022). Long-term control of primary cerebral ALH amyloidoma with focal radiation therapy. *Adv Radiat Oncol*, 100831. DOI 10.1016/j.adro.2021.100831. \*Contributed equally
- 15.) Vollmer BL\*, **Wolf AB**\*, Silau S, Corboy JR, Alvarez E (2022). Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis. *Front Neurol*, 799138. DOI 10.3389/fneur.2021.799138. \*Contributed equally
- 16.) **Wolf AB** & Alvarez E (2022). Ublituximab: A novel anti-CD20 therapy for multiple sclerosis. *touchREVIEWS in Neurology*. 18:117-121. DOI 10.17925/USN.2022.18.2.117.
- 17.) Shah AA\*, **Wolf AB**\*, Declusin A, Coleman K, Kammeyer R, Khan B, Corboy JR (2022). Challenging cases in neuroimmunology. *Semin Neurol*. 42: 695-707. DOI 10.1055/s-0042-1760100. \*Contributed equally
- 18.) **Wolf AB**, Money KM, Chandnani A, Daley CL, Griffith DE, Chauhan L, Coffman N, Piquet AL, Tyler KL, Zimmer S, Montague BT, Mann S, Pastula DM (2023). *Mycobacterium abscessus* meningitis associated with stem cell treatment during medical tourism. *Emerg Infect Dis*. 29: 23-0317. DOI 10.3201/2908.230317.
- 19.) **Wolf AB**, Palace J, Bennett JL (2023). Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD). *Curr Treat Options Neuro*. 25: 437-453. DOI 10.1007/s11940-023-00776-1.
- 20.) **Wolf AB**, Alvarez E, Corboy JR (2024). Comparative efficacy of disease-modifying treatments for relapsing multiple sclerosis - variations in real-world experience. *JAMA Neurol*. 81: 87, DOI 10.1001/jamaneurol.2023.4395.
- 21.) **Wolf AB** & Corboy JR. Escalation to anti-CD20 treatment for multiple sclerosis following natalizumab-associated progressive multifocal leukoencephalopathy. *Neurol Clin Pract*, *in press*.

## CHAPTERS

---

- 1.) **Wolf AB** & Shah AA. Clinical trials in multiple sclerosis. *MedLink Neurology*. Updated 12/2023.

## ABSTRACTS & POSTERS

---

- 1.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the common late-onset Alzheimer's disease susceptibility gene. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 5/2009.
- 2.) Valla J, Braden BB, Lind J, Young N, Engler L, Garcia A, Bowman B, **Wolf AB**, Page K, Kusne Y, Emerson Lombardo N, Bimonte-Nelson H. Comprehensive polynutrient dietary supplementation improves cognition in 3xTG mice. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.
- 3.) **Wolf AB**, Kusne Y, Valla J, Yaari R, Beach TG, Roher A, Corneveaux JJ, Huentelman MJ, Caselli RJ, Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adults with the major Alzheimer's disease susceptibility gene. Society for Neuroscience Annual Meeting, Chicago, IL, 10/2009.
- 4.) Emerson Lombardo N, Valla J, Braden BB, Lind J, Bimonte-Nelson H, Engler L, Garcia A, Young N, Auerbach SH, Bowman B, **Wolf AB**, Page K, Kusne Y, Volicer L. Nutritional supplement combination therapy improves cognition in 3xTG AD mice and will be tested in cognitively normal adults. Alzheimer's Disease International Annual Conference, Thessaloniki, Greece, 3/2010.
- 5.) **Wolf AB**, Valla J, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. Arizona Alzheimer's Consortium Annual Conference, Glendale, AZ, 5/2010.
- 6.) Valla J, **Wolf AB**, Braden BB, Young N, Engler L, Garcia A, Bowman B, Kusne Y, Hatch M, Emerson Lombardo N, Bimonte-Nelson H. Polynutrient dietary supplementation corrects brain mitochondrial biomarkers and improves cognition in the 3xTG mouse model of Alzheimer's disease. International Academy on Nutrition and Aging Annual Meeting, Santa Ana Pueblo, NM, 7/2010.
- 7.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. Arizona Neurosurgical Society Annual Meeting, Marana, AZ, 10/2011.
- 8.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. Society for Neuro-Oncology Annual Scientific Meeting, Garden Grove, CA, 11/2011.
- 9.) **Wolf AB**, Konkowski N, Henderson LB, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. International Conference on Brain Energy Metabolism: Bioenergetics of Neurological Disease and Aging, Pacific Grove, CA, 4/2012.
- 10.) Snyder LA, **Wolf AB**, Porter RW, Smith KA, Spetzler RF, Sanai N. The impact of the extent of resection on malignant transformation of pure oligodendrogliomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 4/2012.

11.) Oppenlander ME, **Wolf AB**, Porter RW, Nakaji P, Smith KA, Spetzler RF, Sanai N. An extent of resection threshold for recurrent glioblastomas. American Association of Neurological Surgeons Annual Scientific Meeting, Miami, FL, 4/2012.

12.) **Wolf AB**, Konkowski N, Henderson L, Allred R, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. Arizona Alzheimer's Consortium Annual Conference, Phoenix, AZ, 5/2012.

13.) Henderson LB, Allred R, **Wolf AB**, Alex M, Konkowski N, Valla J. Foundations of Alzheimer's bioenergetic vulnerability in APOE  $\epsilon$ 4 carriers. American Osteopathic Association Research Conference, San Diego, CA, 10/2012.

14.) **Wolf AB**, Felsen G. The function of GABAergic neurons in the superior colliculus during decision making. University of Colorado Neuroscience Program Annual Research Conference, Estes Park, CO, 11/2015.

15.) Essig J, **Wolf AB**, Felsen G. Functional role of inhibitory superior colliculus neurons in target selection. Society for Neuroscience Annual Meeting, San Diego, CA, 11/2016.

16.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. University of Colorado Department of Neurology Annual Research Retreat, Virtual, 6/2021.

17.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies. American Neurological Association Annual Meeting, Virtual, 10/2021.

18.) **Wolf AB**, Pratt RW, Crooks K, Borko T, Parra Gonzales J, Vollmer TL, Frazer-Abel A, Alvarez EA. Humoral response to mRNA-based COVID-19 vaccination in patients with multiple sclerosis on anti-CD20 disease modifying therapies.ECTRIMS Annual Congress, Virtual, 10/2021.

19.) Crane PD, Ardakani R, Alvarez E, Chauhan L, Matthews E, Shah A, Pastula D, Money K, Piquet A, Tyler K, **Wolf AB**. Neuroinvasive West Nile virus associated with anti-CD20 treatment for CNS inflammatory diseases. ACTRIMS Annual Forum, West Palm Beach, FL. 3/2024.

20.) Rajarajan P, Quinn C, Gill A, Kopinsky H, Bacon T, **Wolf AB**, Murray J, Probasco J, Galetta K, Kantor D, Alvarez E, Coyle P, Conway S, Bhattacharyya S, Kister I. Multi-institutional study of neurologic outcomes in people with multiple sclerosis who are treated with immune checkpoint inhibitors (ICIs) for oncologic indications. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

21.) Ardakani R, Schmitt B, Carlson A, **Wolf AB**, Tyler K, Pastula D, Piquet A. JC Virus Granule Cell Neuronopathy Mimicking Paraneoplastic Cerebellar Degeneration. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

22.) Sollero CEV, Money KM, **Wolf AB**, Schmitt B, Sillau S, Nair KV, Piquet AL, Bennett JL, Carlson AM. Epidemiology of Seropositive Neuromyelitis Optica Spectrum Disorder in a Large US Population. American Academy of Neurology Annual Meeting, Denver, CO. 4/2024.

#### PROFESSIONAL CERTIFICATIONS

---

Advanced Cardiac Life Support (ACLS), initial 5/2018  
Basic Life Support (BLS), renewed 4/2022  
CITI Program, renewed 2/2022  
DEA Controlled Substance Registration Certificate, initial 6/2022  
Expanded Disability Status Scale (EDSS), Level C, initial 4/2023  
NIH Stroke Scale, renewed 5/2021

#### PROFESSIONAL MEMBERSHIPS

---

American Academy of Neurology  
American Neurological Association  
Colorado Neurological Society  
Siegel Rare Neuroimmune Association

#### JOURNAL REVIEW ACTIVITY

---

Acta Ophthalmologica  
Brain and Behavior  
Cureus  
JAMA Neurology  
Journal of Clinical Pharmacy and Therapeutics  
Journal of Neurology  
Neuroimmunology Reports  
Neurology  
Neurology Clinical Practice  
Neurology Education  
Neurology Neuroimmunology & Neuroinflammation  
Neurology and Therapy

#### GRANT SUPPORT

---

Project: Integration of multidomain digital biomarkers to detect progression in multiple sclerosis  
Role: Co-PI (w/ Enrique Alvarez, MD/PhD)  
Funding Source: Rocky Mountain Multiple Sclerosis Center  
Dates: 7/1/2023-7/1/2024  
Total Costs: \$9907

Project: Integration of multidomain digital and blood biomarkers to detect worsening in multiple sclerosis  
Role: PI  
Funding Source: Mowry Family  
Dates: 12/1/2023-2/28/2025  
Total Costs: \$61496

## CLINICAL TRIALS

---

NCT03972306. A study to investigate the pharmacokinetics, safety, and tolerability of subcutaneous ocrelizumab administration in participants with multiple sclerosis.

Role: Sub-investigator, 2022-2023

NCT04544449. A study to evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult participants with primary progressive multiple sclerosis (FENtrepid).

Role: Sub-investigator, 2022-present

NCT05503264. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in patients with anti-N-methyl-D-aspartic acid receptor (NMDAR) or anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis (CIELO).

Role: Sub-investigator, 2024-present

NCT04586010. A study to evaluate the efficacy and safety of fenebrutinib compared with teriflunomide in relapsing multiple sclerosis (FENhance).

Role: Sub-investigator, 2024-present

## TEACHING ACTIVITY

---

### University of Colorado Medical Students:

#### *IDPT 5022 Nervous System*

Neuropathology Lab – Neuroimmunology, 3/7/2022 (170 students, 4 hours)

Neuropathology Lab – Neuroimmunology, 3/6/2023 (170 students, 2 hours)

Neuropathology Lab – Neuroimmunology, 3/5/2024 (85 students, 2 hours)

#### *IDPT 7041 Neurologic Care*

Problem Based Learning – Acute Stroke, 9/3/2020 (12 students, 2 hours)

#### *IDPT 8037 Advanced Neuroscience*

Neuropathology Lab – Neuroimmunology, 11/16/2022 (170 students, 4 hours)

Neuroimmunology Cases, 12/15/2022 (170 students, 1 hour)

Neuroinflammation Cases, 10/25/2023 (170 students, 1 hour) (w/ Kelli Money, MD/PhD)

Team Based Learning – Neuroinflammation (170 students, 2 hours) (w/ Kelli Money, MD/PhD)

#### *IDPT 7006 Foothills Basecamp Transition to Clerkships*

Oral Presentations, 9/6/2023 (4 students, 2 hours)

#### *IDPT 8060 Alpine basecamp Transition to Advanced Clerkships*

Summarizing Evidence in Clinical Presentations, 1/31/2024 (8 students, 2 hours)

### University of Colorado Neurology Residents:

#### *Didactic Lectures, ~24 residents, 1 hour*

Clinical Anatomy Cases – Spinal Cord, 12/2/2020

Neuroimmunology Board Review, 1/6/2021

Neuroradiology Cases – Neuroimmunology & Neuro-ophthalmology, 1/20/2021

Neuroradiology Cases – Neuroinfectious Disease, 6/16/2021 (w/ Madeline Garza, MD)

Neurological Emergencies in Pregnancy, 8/25/2021 (w/ Sharon Poisson, MD)  
Burnout in Neurology: Definitions, Quantification, and Intervention, 9/1/2021  
Epilepsy Neuroimaging, 10/27/2021  
Epilepsy Clinical Cases, 10/27/2021 (w/ Dave Jeon, MD)  
Pediatric Neuroimmunology, 1/12/2022  
Neuroimmunology Board Review, 1/19/2022  
Neuroradiology Cases – Neurodegenerative Disease, 5/11/2022  
Neuro-oncology Board Review, 5/18/2022  
Neurological Emergencies in Pregnancy, 8/24/2022 (w/ Sharon Poisson, MD)  
Pediatric Neuroimmunology, 11/30/2022  
Neurological Emergencies in Pregnancy and the Postpartum Period, 8/23/2023  
Neuroradiology: MS, NMOSD, and MOGAD, 11/15/2023 (w/ Justin Honce, MD)

*Team-Based Learning, ~24 residents, 2 hours*  
Neuroimmunology, 12/5/2023

#### *Written Materials*

Neurology Survival Guide – Neuroimmunology, 6/2021 (w/ Anthony Declusin, MD)  
Practical Overview of Multiple Sclerosis Diagnosis & Management, revised 2/2024

#### CLINICAL SUPERVISION

---

##### University of Colorado Medical Students:

University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 7/2023-present  
DOCS Mentor for MSI Hanna Vanderpool, 2023-2024

##### University of Colorado Neurology Residents:

Denver Health neuroimmunology clinic, ~6 half-days yearly, 7/2022-present  
University of Colorado Hospital continuity clinics, ~1 half-day monthly, 7/2023-present  
University of Colorado Hospital neuroimmunology clinic, ~2 half-days monthly, 7/2023-present  
DAWN Clinic, ~1 evening monthly, 7/2023-present

##### University of Colorado Neuroimmunology Fellows:

University of Colorado Hospital neuroimmunology clinic, ~4 half-days monthly, 7/2023-present

#### INTRAMURAL PRESENTATIONS

---

##### University of Colorado Neurology Grand Rounds:

Clinical Case Review, 4/12/2023 (w/ Anna Shah, MD & Jennifer Simpson, MD)  
BTK Inhibitors: The Next Wave in MS Treatment, 4/19/2023 (w/ Anthony Declusin, MD)

##### University of Colorado Neurology Professor Rounds:

“A 61-year-old man with headache” – Isolated infratentorial PRES, 9/27/2019  
“A 55-year-old woman with hemiparesis” – Primary cerebral amyloidoma, 11/22/2019  
“An 85-year-old man with dyspnea” – Pembrolizumab-associated myasthenia gravis, 7/31/2020

##### University of Colorado Neuroimmunology Division Conference:

BTK Inhibitors in Multiple Sclerosis, 3/4/2021  
Remyelination Therapies: What’s Next?, 7/21/2022  
Leukodystrophies: Multiple Sclerosis Mimicry and Misdiagnosis, 1/19/2023



Alternative Dosing Strategies for anti-CD20 Disease-modifying Therapies, 3/16/2023  
Radiologic Differentiation of Tumefactive Demyelination, 5/18/2023

University of Colorado Neurology Research Retreat:

Arguments for Disease-modifying Therapy De-escalation in Multiple Sclerosis, 6/1/2022

EXTRAMURAL PRESENTATIONS

---

1.) Acute Management of NMOSD, From Clinical Studies to the Real World: Sharing Clinical Experience in the Treatment of NMOSD. Horizon Therapeutics Symposium. Denver, CO. 11/2023.

2.) Use and Misuse of Stem Cell Treatments and Implications for Medical Tourism. Stem Cell Transplantation in Neurology: the Good, the Bad, and the Ugly. American Academy of Neurology Annual Meeting, Denver, CO, 4/2024

INTRAMURAL SERVICE

---

University of Colorado Neurology Residency Program

Chief Resident, 7/2021-6/2022

- Organized weekly didactics sessions (4 hours / week) with subspecialty faculty
  - Organized weekly Professor Rounds (departmental case conference) with residents
  - Mentored residents on case presentations and other scholarly/research activities
  - Led program overview presentations and small group sessions with residency applicants
  - Participation on University of Colorado Hospital GME Quality Improvement Committee Resident Selection Committee, 2022-2023, 2023-2024
- Faculty Director, Didactics Neuroimmunology Block, 7/2023-present  
Faculty Director, Journal Club, 7/2023-Present

University of Colorado MD Program:

MD Admissions Interviewer, 2023-2024

BA/BS-MD Admissions Interviewer, 2023-2024

EXTRAMURAL SERVICE

---

ACTRIMS fellowship webinar series, organizing committee, 2022-2023

American Academy of Neurology Annual Meeting, session monitor, Boston, MA, 4/2023

CLINICAL OUTREACH

---

AHEC health screenings, National Western Stock Show, Denver, CO, volunteer, 1/2016

DAWN Clinic, Aurora, CO, volunteer physician, 5/2022-present (1 evening monthly)

EDUCATIONAL OUTREACH

---

Denver Museum of Nature & Science, Brain Awareness Week, Denver, CO, 3/2016

Rio Grande Inn, lecture on Alzheimer's disease, La Jara, CO, 7/2016

Helmet Heads, TBI prevention outreach, Aurora, CO, 5/2017

National MS Society ECHO MS Mountain Hub, case presentation, 1/2023

Rocky Mountain MS Center, Conversations in MS, Pueblo, CO, 10/2023

National MS Society ECHO MS Mountain Hub, lecture on urogenital dysfunction in MS, 3/2024  
Rocky Mountain MS Center, Spring Education Summit, 4/2024

#### HONORS, AWARDS, & RECOGNITION

---

Summa cum laude, Arizona State University, 5/2010  
Recognition of excellence on medical student evaluations, University of Colorado SOM, 8/2021  
Extra Mile Award, University of Colorado Neurology Residency Program, 6/2022  
Resident Research Award, University of Colorado Neurology Residency Program, 6/2022  
Recognition for high-performance on clinician listening metric, UCHealth, 7/2023

#### FINANCIAL DISCLOSURES

---

I have received funding for research from the Rocky Mountain MS Center and the Mowry Family. I have received payments for clinical trials from Genentech, consulting from TG Therapeutics and Genentech, and educational programming from MedLink Neurology and Horizon Therapeutics.

*Updated 4/2024*